The PI3K-AKT-mammalian target of rapamycin (mTOR) pathway regulates cell metabolism, proliferation and survival, and aberrant activation of this pathway has been shown to drive the progression of malignant tumors.1
Visit the Novartis Oncology Pipeline to learn more about the following PI3Ka inhibitors in development:
a. phosphoinositide 3-kinaseb. protein kinase B
All compounds are either investigational or studied in new indications. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.
This site is intended for a global audience.